Valziflocept
Based on 1 Customer Validation
Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.00%
- CAS No.: 1804910-11-9
- Masse moléculaire:19.693 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Valziflocept significantly inhibits phagocytosis of IgG-opsonised murine red blood cells by thioglycolate-elicited peritoneal macrophages from female NZB/NZW F1 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Valziflocept (50-150 μg/week; s.c.; weekly; 4 weeks) delays onset of lupus pathology and improves survival in NZB/NZW F1 mice, while valziflocept (100 μg/week; s.c.; weekly; until death or study end (therapeutic)) significantly prolongs survival despite established kidney damage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/1 (male, age-matched, collagen-induced arthritis model)[1]
-
Dosage:200 μg per dose
-
Administration:i.v.; 5 occasions with 3-day intervals
-
Result:Reduced mean arthritic score to 6.1 at 12 days after first treatment and 14.2.
Reduced serum IgG anti-collagen type II antibody levels significantly 2 weeks after treatment start.
Reduced TNF-α and IL-6 mRNA levels significantly in lymph nodes.
Reduced TGF-β1, TGF-β2, TGF-β3, and MIF mRNA levels in synovial tissue.
-
Animal Model:NZB/NZW F1 (female, 5-8 weeks old at study start)[2]
-
Dosage:50 μg/week; 100 μg/week; 150 μg/week
-
Administration:s.c.; weekly; 4 weeks
-
Result:Significantly delayed onset of proteinuria with 3×50 μg/week prophylactic treatment.
Prolonged survival by 11.5 weeks with 3×50 μg/week prophylactic treatment.
Delayed weight loss and delayed development of anaemia with 3×50 μg/week prophylactic treatment.
Reduced histopathological signs of glomerulonephritis, and suppressed mesangial matrix expansion, Bowman space proliferation, and crescent formation in kidneys with 3×50 μg/week prophylactic treatment.
Showed a non-significant trend towards prolonged survival with 1×150 μg/week prophylactic treatment.
Significantly prolonged survival with 1×100 μg/week therapeutic treatment.
Reduced histopathological signs of glomerulonephritis, and suppressed mesangial matrix expansion, Bowman space proliferation, and crescent formation in kidneys with 1×100 μg/week therapeutic treatment.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FCGR2B (immunoglobulin G Fc receptor low affinity IIb, Fc gamma RIIb, CD32, CD32b)
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1804910-11-9
-
Appearance Liquid
-
Masse moléculaire 19.693 kDa
-
Color Colorless to light yellow
-
SMILES
[Valziflocept]
-
Synonyms
BAX1810; TAK-752; SM101
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Magnusson SE, et al. Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb. Clin Immunol. 2008;127(2):225-233. [Content Brief]
[2]. Werwitzke S, et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis. 2008 Feb;67(2):154-61. [Content Brief]
[3]. Zuercher AW, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Valziflocept Related Classifications
HY-P99529 Related Classifications
Powered by Bioz
- Valziflocept
- 1804910-11-9
- BAX1810
- TAK-752
- SM101
- BAX 1810
- BAX-1810
- TAK752
- TAK 752
- TAK-752
- SM101
- SM 101
- SM-101
- Fc Receptor (FcR)
- macrophages
- inflammatory cytokines
- murine erythrocytes
- IgG anti-collagen type II antibodies
- NZB/NZW F1 mice
- mouse IgG
- Fcγ receptor
- collagen-induced arthritis
- systemic lupus erythematosus
- immune complexes
- Inhibitor
- inhibitor
- inhibit